ADDED
Form 10-K Summary 68 i Our financial statements are stated in thousands United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles ( U.S.
In this Annual Report on Form 10-K (this Annual Report ), unless otherwise specified, all dollar, amounts are expressed in United States Dollars.
As used in this Annual Report, unless the context otherwise requires, the terms Pluri , the Company , we , us , and our refer to Pluri Inc., together with its wholly owned Israeli subsidiary, Pluri Biotech Ltd.
and the subsidiaries of Pluri Biotech Ltd., including its wholly owned Israeli subsidiary, Coffeesai Ltd.
( Coffeesai ), its majority-owned Israeli subsidiaries, Kokomodo Ltd.
( Ever After Foods ) and its wholly owned German subsidiary, Pluristem GmbH (collectively, the Subsidiaries ).
Developments in international trade policy, such as tariffs, sanctions, and other trade barriers imposed by the U.S.
or other countries, which could affect our sourcing and distribution channels, increase costs, or otherwise negatively impact our operations and financial results; and our ability to continue to comply with the rules for continued listing on the Nasdaq Capital Market.
Risk Factors , and expressed from time to time in our filings with the Securities and Exchange Commission (the SEC ), could cause actual results and developments to be materially different from those expressed in or implied by such statements.
Our business and operations are subject to substantial risks, which increase the uncertainty inherent in the forward-looking statement contained in this Annual Report.
REMOVED
Form 10-K Summary 60 i Our financial statements are stated in thousands United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles, or U.S.
In this annual report, unless otherwise specified, all dollar, amounts are expressed in U.S.
As used in this annual report, the terms we , us , our , the Company , and Pluri mean Pluri Inc., our wholly owned Israeli subsidiary, our majority owned Israeli subsidiary, and the wholly owned subsidiary of our Israeli subsidiary in Germany, unless otherwise indicated or required by the context.
All information in this Annual Report on Form 10-K or Annual Report, relating to shares or price per share reflects the 1-for-8 reverse stock split effected by us on April 1, 2024.
Risk Factors , and expressed from time to time in our filings with the Securities and Exchange Commission, or SEC, could cause actual results and developments to be materially different from those expressed in or implied by such statements.
In addition, historic results of scientific research, clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions.
Overview We are a biotechnology company with an advanced cell-based technology platform.
We have developed a unique three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.
Our operations are focused on the research, development and manufacturing of cell-based products and the business development of cell therapeutics and cell-based technologies providing potential solutions for various industries.
has a wholly owned subsidiary, Pluri Biotech Ltd., or the Subsidiary, which is incorporated under the laws of the State of Israel.